In Brief: FDA Biological Response Modifiers Committee
This article was originally published in The Gray Sheet
Executive Summary
FDA Biological Response Modifiers Committee: Slated to meet Feb. 28 and 29 at the Holiday Inn in Bethesda, Maryland. On Feb. 28 the committee will discuss a premarket approval application for CellPro's Ceprate SC device for selection of CD34+ progenitor/stem cells and receive an update on "stem cell policy," according to a Jan. 31 notice in the Federal Register. On Feb. 29 the committee will discuss issues in early clinical trial development for in utero stem cell transplantation and the draft addendum to the 1991 points-to-consider on human somatic cell and gene therapy. Contact FDA's William Freas or Pearline Muckelvgene, 301/827-0314...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.